2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now

The article pitches Pfizer and Bristol Myers Squibb as dividend-supported rebound stories amid patent cliffs. Pfizer’s forward dividend yield is cited at 7.1% (up 51.3% over the past decade) with its stock trading around 8.2x forward earnings, while BMY is cited at a 4.3% forward yield (up 65.8%) trading near 9x forward earnings, both supported by pipeline progress such as Pfizer’s phase 3 PF’4404 and BMY’s FDA Fast Track Milvexian. Overall, the news is constructive but is primarily investor-oriented commentary rather than a discrete new catalyst likely to move markets broadly.

Analysis

This reads more like a valuation-screen promotion than a catalyst. The market mechanism is not “cheap dividend stocks,” it is whether the next 12-24 months contain enough de-risking events to stop these from trading as melting-ice-cube cash cows; absent that, high yields can remain a symptom of impaired confidence rather than opportunity. For PFE, the key issue is not yield support but whether a few late-stage wins can offset patent erosion before earnings power structurally resets lower; for BMY, the question is whether the market will pay for a slower but more credible transition from legacy franchise dependence to newer launches.

Relative winners are likely the companies that benefit from the same therapeutic areas without the same overhang. JNJ is a cleaner “next-gen anticoagulant” beneficiary if Milvexian data are strong, while BNTX gains optionality from pipeline success but still faces binary clinical risk. In oncology, any strength in BMY’s subcutaneous Opdivo defense is more a share-retention story than a category expansion story; the bigger second-order risk is that competitors like MRK and other IO players use this window to lock in formulary and combination-regimen share, making even successful launches less accretive than bulls assume.

Contrarianly, the consensus may be underpricing how long it takes for pipeline wins to translate into EPS, especially when mature pharma trades are driven by patent math, not headline optimism. The downside case is a sequence of “good enough” trial updates that never become franchise-scale revenue, leaving both names stuck at low multiples and forcing capital return to do the heavy lifting. What would falsify the bearish read: a meaningful upward revision to 2026-2028 EPS, or multiple phase 3 wins with clear peak-sales potential; otherwise these remain yield plays, not true re-rating stories.

Key Decisions for Investors

• Prefer BMY over PFE on a 6-12 month relative-value basis: long BMY / short PFE with a target that BMY closes part of the valuation gap if subQ Opdivo and Milvexian continue to de-risk; thesis breaks if PFE delivers a true multi-asset pipeline surprise or BMY guidance weakens.
• If expressing a cautious view, avoid chasing the headline yields and instead look for entry only after clinical/event risk: buy PFE or BMY on a 5-7% post-data pullback, not ahead of binary readouts; otherwise the yield can be value-trap compensation rather than alpha.
• Long JNJ as the cleaner second-order beneficiary versus BMY: JNJ gets optionality from Milvexian without needing to re-rate its entire equity story; this is a lower-beta way to play anticoagulant innovation over 12-24 months.
• Watch MRK as the structural loser if BMY’s Opdivo subcutaneous conversion meaningfully improves convenience and retention; if adoption is slow, the trade thesis is invalidated and MRK remains the better oncology comp.
• No immediate options trade recommended unless a catalyst calendar emerges; the current signal is more about income durability than near-term re-rating, so wait for confirmed pipeline data before using calls or puts.